Engineering Extracellular Vesicles: Enhancing Therapeutic Potential and Precision in Disease Treatment

Rhenium is happy and proud to announce partnership with Jotbody, a pioneering biotechnology company dedicated to the development of innovative solutions in the field of extracellular vesicles (EVs) and nanobodies. Jotbody specializes in their functionalization, including nucleic acid loading and surface modification, enabling the creation of tailored therapeutic platforms that harness the natural properties of EVs, paving the way for groundbreaking advancements in drug delivery, diagnostics, and targeted therapies. We believe that this is an important addition to our ability to provide a total workflow for nano-scale research. 

We would like to invite you to a special webinar to introduce Jotbody’s solutions focusing on engineered extracellular vesicles. Learn more about how engineered EVs can maximize therapeutic efficacy and minimize off-target effects.

Presented by:
Dr. Marco Pirisinu, PhD, Jotbody